Stay updated with breaking news from John Beigel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For people eager to put the health crisis behind them, the relief of being vaccinated is being replaced by a new worry. Is immunity a ticking clock? Should they plan a family wedding this fall? Will everyone need booster shots? When?
increase font size Scientists are figuring out if we will need another coronavirus shot – and which one For people eager to put the health crisis behind them, the relief of being vaccinated is being replaced by a new worry. Is immunity a ticking clock? By Carolyn Y. JohnsonThe Washington Post Share U.S. scientists are expanding efforts to evaluate when fully vaccinated people will need booster shots – and, if so, whether people can switch brands – in the latest chapter of the global quest to stop the pandemic. For people eager to put the health crisis behind them, the relief of being ...
Quotes delayed at least 15 minutes. Real-time quotes provided by BATS BZX Real-Time Price. Market Data provided by Interactive Data (Terms & Conditions). Powered and Implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund and ETF data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions. This material may not be published, broadcast, rewritten, or redistributed. ©2021 FOX News Network, LLC. All rights reserved. FAQ - Updated Privacy Policy
Credit: NIAID and Colorado State University WHAT: A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical company Regeneron, located in Ta...